165 related articles for article (PubMed ID: 11912139)
21. Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism ratio.
Straub M; Auderset A; de Leval L; Piazzon N; Maison D; Vozenin MC; Ollivier J; Petit B; Sigman DM; Martínez-García A
Sci Rep; 2023 Nov; 13(1):19796. PubMed ID: 37957187
[TBL] [Abstract][Full Text] [Related]
22. Tissue Expression of Growth Differentiation Factor 11 in Patients with Breast Cancer.
Chen CC; Lee TL; Tsai IT; Hsuan CF; Hsu CC; Wang CP; Lu YC; Lee CH; Chung FM; Lee YJ; Wei CT
Diagnostics (Basel); 2024 Mar; 14(7):. PubMed ID: 38611614
[TBL] [Abstract][Full Text] [Related]
23. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.
Bocca C; Ievolella M; Autelli R; Motta M; Mosso L; Torchio B; Bozzo F; Cannito S; Paternostro C; Colombatto S; Parola M; Miglietta A
Expert Opin Ther Targets; 2014 Feb; 18(2):121-35. PubMed ID: 24325753
[TBL] [Abstract][Full Text] [Related]
24. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.
Kundu M; Butti R; Panda VK; Malhotra D; Das S; Mitra T; Kapse P; Gosavi SW; Kundu GC
Mol Cancer; 2024 May; 23(1):92. PubMed ID: 38715072
[TBL] [Abstract][Full Text] [Related]
25. The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.
Ren R; Xiong C; Ma R; Wang Y; Yue T; Yu J; Shao B
MedComm (2020); 2023 Aug; 4(4):e323. PubMed ID: 37547175
[TBL] [Abstract][Full Text] [Related]
26. Cooperation between Prostaglandin E2 and Epidermal Growth Factor Receptor in Cancer Progression: A Dual Target for Cancer Therapy.
Finetti F; Paradisi L; Bernardi C; Pannini M; Trabalzini L
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190301
[TBL] [Abstract][Full Text] [Related]
27. Hepatic circadian and differentiation factors control liver susceptibility for fatty liver disease and tumorigenesis.
Fekry B; Ribas-Latre A; Drunen RV; Santos RB; Shivshankar S; Dai Y; Zhao Z; Yoo SH; Chen Z; Sun K; Sladek FM; Younes M; Eckel-Mahan K
FASEB J; 2022 Sep; 36(9):e22482. PubMed ID: 35947136
[TBL] [Abstract][Full Text] [Related]
28. HIF and COX-2 expression in triple negative breast cancer cells with hypoxia and 5-fluorouracil.
Mori N; Mironchik Y; Wildes F; Wu SY; Mori K; Krishnamachary B; Bhujwalla ZM
Curr Cancer Rep; 2020 Dec; 2(1):54-63. PubMed ID: 35814639
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant and cytotoxic activities of selected salicylidene imines: experimental and computational study.
Branković J; Krokidis MG; Dousi I; Papadopoulos K; Petrović ZD; Petrović VP
Mol Divers; 2022 Dec; 26(6):3115-3128. PubMed ID: 35147861
[TBL] [Abstract][Full Text] [Related]
30. PACER lncRNA regulates COX-2 expression in lung cancer cells.
Desind SZ; Iacona JR; Yu CY; Mitrofanova A; Lutz CS
Oncotarget; 2022; 13():291-306. PubMed ID: 35136486
[TBL] [Abstract][Full Text] [Related]
31. The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.
Walker OL; Dahn ML; Power Coombs MR; Marcato P
Front Oncol; 2021; 11():791696. PubMed ID: 35127497
[TBL] [Abstract][Full Text] [Related]
32. Cancer Chemoprevention: A Strategic Approach Using Phytochemicals.
G MS; Swetha M; Keerthana CK; Rayginia TP; Anto RJ
Front Pharmacol; 2021; 12():809308. PubMed ID: 35095521
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis.
Renaldi K; Simadibrata M; Rahadiani N; Handjari DR; William A; Sinuraya F; Makmun D
Turk J Gastroenterol; 2021 Nov; 32(11):956-970. PubMed ID: 34872897
[TBL] [Abstract][Full Text] [Related]
34. Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression.
Shah H; Pang L; Qian S; Sathish V
NPJ Breast Cancer; 2021 Sep; 7(1):122. PubMed ID: 34535685
[TBL] [Abstract][Full Text] [Related]
35. Dyslipidemia in breast cancer patients increases the risk of SAR-CoV-2 infection.
Shakartalla SB; Alhumaidi RB; Shammout ODA; Al Shareef ZM; Ashmawy NS; Soliman SSM
Infect Genet Evol; 2021 Aug; 92():104883. PubMed ID: 33905884
[TBL] [Abstract][Full Text] [Related]
36. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
Salemme V; Centonze G; Cavallo F; Defilippi P; Conti L
Front Oncol; 2021; 11():610303. PubMed ID: 33777750
[TBL] [Abstract][Full Text] [Related]
37. S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue.
Jindal S; Pennock ND; Klug A; Narasimhan J; Calhoun A; Roberts MR; Tamimi RM; Eliassen AH; Weinmann S; Borges VF; Schedin P
NPJ Breast Cancer; 2020 Nov; 6(1):62. PubMed ID: 33298921
[TBL] [Abstract][Full Text] [Related]
38. Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity.
Finetti F; Travelli C; Ercoli J; Colombo G; Buoso E; Trabalzini L
Biology (Basel); 2020 Dec; 9(12):. PubMed ID: 33271839
[TBL] [Abstract][Full Text] [Related]
39. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.
Risha Y; Minic Z; Ghobadloo SM; Berezovski MV
Sci Rep; 2020 Aug; 10(1):13572. PubMed ID: 32782317
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer pathogenesis is linked to the intra-tumoral estrogen sulfotransferase (hSULT1E1) expressions regulated by cellular redox dependent Nrf-2/NF
Nazmeen A; Chen G; Ghosh TK; Maiti S
Cancer Cell Int; 2020; 20():70. PubMed ID: 32158360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
